A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age7+
SponsorChildren's Oncology Group
About this trial
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.
Eligibility criteria
Qualifiers
Patient must be >= 7 years of age at the time of enrollment (age to perform an MRI without sedation).
History of pathologically confirmed classical Hodgkin Lymphoma (cHL) initially diagnosed when the patient was >= 2 and < 22 years of age.
As part of frontline therapy for cHL, the patient must have received a cumulative doxorubicin equivalent anthracycline dose of ≥ 200 mg/m² as estimated in doxorubicin isotoxic equivalents dose conversion calculation.
Note: History of COG therapeutic trial participation is not required. Institutional records (e.g., clinic note, treatment summary, chemotherapy roadmap) can be used as reference documentation of receipt of anthracycline dose.
Disqualifiers
Medical contraindication to undergoing a non-contrast cardiac MRI.
Patients with nodular lymphocyte-predominant HL.
Received cancer therapy in addition to that for primary Hodgkin Disease (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).
History of CTCAE grade 3 or higher cardiovascular disease or condition known to exist prior to the patient's initial diagnosis of cHL.
Trial design
Treatments tested in this trial
- Archive Sample Retrieval
- Biospecimen Collection
- Electronic Health Record Review
- Magnetic Resonance Imaging
- Survey Administration
Treatment groups
190 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov